Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL147940 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Mucic Acid SCHEMBL7527588 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Mucic Acid SCHEMBL7538629 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL8465565 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL16609822 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL433662 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL338748 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL338310 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL21778048 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL16609840 | 1.00 | PDE4A (1.00) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025263641-A1 | COMPOSITION COMPRISING GLYCOLIPID, CATIONIC POLYMER AND (POLY)HYDROXY ACID | L'OREAL (FR) | 2025-12-26 | — | — | WO | claimed |
| EP-4608352-A1 | AQUEOUS MAKE-UP-REMOVING COMPOSITION HAVING A MILD PEELING EFFECT | L'OREAL (FR) | 2025-09-03 | — | — | EP | claimed |
| US-12122745-B2 | Processes for preparing aldaric, aldonic, and uronic acids | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2024-10-22 | — | — | US | claimed |
| WO-2024088996-A1 | AQUEOUS MAKE-UP-REMOVING COMPOSITION HAVING A MILD PEELING EFFECT | L'OREAL (FR) | 2024-05-02 | — | — | WO | claimed |
| CN-117229272-A | Preparation method of enggliflozin | 安徽美诺华药物化学有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230028813-A1 | PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS | ARCHER DANIELS MIDLAND CO (US) | 2023-01-26 | — | — | US | claimed |
| EP-4112594-A1 | PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS | Archer-Daniels-Midland Company (US) | 2023-01-04 | — | — | EP | claimed |
| EP-3822247-B1 | PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS | ARCHER DANIELS MIDLAND CO (US) | 2022-06-08 | — | — | EP | claimed |
| EP-3997164-A1 | USE OF PHENOLICALLY SUBSTITUTED SUGAR DERIVATIVES AS STABILISERS, PLASTIC COMPOSITION, METHOD FOR STABILISING PLASTICS AND PHENOLICALLY SUBSTITUTED SUGAR DERIVATIVES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-05-18 | — | — | EP | claimed |
| US-20260144811-A1 | HYDROGEL FOR BODY CAVITY INJURY TREATMENT AND BODY CAVITY INJURY TREATMENT KIT | KAGOSHIMA UNIVERSITY (JP) | 2026-05-28 | — | — | US | disclosed |
| CN-122055127-A | Composition for caring keratin materials | 莱雅公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055126-A | Leave-on composition for caring for keratin materials | 莱雅公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4740936-A1 | HYDROGEL FOR BODY CAVITY INJURY TREATMENT AND BODY CAVITY INJURY TREATMENT KIT | Kagoshima University (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12552913-B2 | Use of phenolically substituted sugar derivatives as stabilisers, plastic composition, method for stabilising plastics and phenolically substituted sugar derivatives | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2026-02-17 | — | — | US | disclosed |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2019-10-29 | — | — | US | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9044733-B2 | Method and apparatus for preparing a solution of a shear sensitive material | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9034256-B2 | Method and apparatus for preparing a solution of shear sensitive material | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2015042711-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE, INC. (CA) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144811-A1 | HYDROGEL FOR BODY CAVITY INJURY TREATMENT AND BODY CAVITY INJURY TREATMENT KIT | CUTA, AADAT, OGA | PDE4A 3876/4885LMNA 105/4885USP2 2582/4885 |
| US-20230028813-A1 | PROCESSES FOR PREPARING ALDARIC, ALDONIC, AND URONIC ACIDS | ALDOA, AKR1C4, ADSL | PDE4A 3856/4885LMNA 645/4885USP2 650/4885 |
| US-12552913-B2 | Use of phenolically substituted sugar derivatives as stabilisers, plastic composition, method for stabilising plastics and phenolically substituted sugar derivatives | SORD, GYS1, GYS2 | PDE4A 4863/4885LMNA 1993/4885USP2 4586/4885 |
| US-12122745-B2 | Processes for preparing aldaric, aldonic, and uronic acids | ALDOA, AKR1C4, ADSL | PDE4A 3856/4885LMNA 645/4885USP2 650/4885 |
| US-10456481-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885LMNA 1219/4885USP2 615/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885LMNA 1219/4885USP2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.